Nayereh Pezeshkian
Cardiovascular Disease · Sacramento, CANPI 1538362017
Payments from drug & device makers
Across 84 payments — averaging $83.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Stereotaxis Inc$1K
- Medtronic$1K
- Boston Scientific$445
- Biosense Webster, Inc.$382
- Cardiva Medical, Inc.$317
- plus $241 from 3 others
What the payments were for
- Travel & lodging$4,15059%
- Food & beverage$2,86541%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 27 | $3,115 |
| Stereotaxis Inc | 3 | $1,314 |
| Medtronic(2 entities) | 11 | $1,201 |
| Boston Scientific | 15 | $445 |
| Biosense Webster, Inc. | 10 | $382 |
| Cardiva Medical, Inc. | 12 | $317 |
| Recor Medical Inc | 2 | $167 |
| Biotronik Inc. | 2 | $45 |
| Shockwave Medical, Inc | 2 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$2,618
- Niobe$1,256
- Micra$1,060
- Paradise Ultrasound Renal Denervation System$149
How this compares
$7,015 in reported general payments places this provider in the 65th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 95 | $130,595 |
| XareltoRivaroxaban | 29 | $45,666 |
| MultaqDronedarone Hcl | 12 | $22,875 |
| Metoprolol Succinate | 208 | $4,306 |
| Flecainide Acetate | 23 | $938 |
| Amlodipine Besylate | 133 | $787 |
| Losartan Potassium | 63 | $732 |
| Amiodarone Hcl | 30 | $604 |
| Ranolazine ErRanolazine | 11 | $550 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 22 | $474 |
| Digoxin | 14 | $369 |
| Metoprolol Tartrate | 20 | $315 |
| Carvedilol | 25 | $272 |
| Lisinopril | 22 | $227 |
| Atenolol | 12 | $109 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Sacramento
- Jason RogersSacramento$5.1M
- Gagan SinghSacramento$2M
- Jeffrey SouthardSacramento$1.8M
- Thomas SmithSacramento$942K
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.